Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer

International Journal of Cancer

Volumn 71, Issue 6, 1997, Pages 1049-1055

  Jarvis, Gary A ^a,b,c   Li, Jing ^a   Hakulinen, Juha ^c   Brady, Katharine A ^b   Nordling, Stig ^c   Dahiya, Rajvir ^b   Meri, Seppo ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN;

ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

ADENOCARCINOMA; ANTIGENS, CD59; BLOTTING, WESTERN; COMPLEMENT SYSTEM PROTEINS; HUMANS; MALE; PHOSPHATIDYLINOSITOL DIACYLGLYCEROL-LYASE; PHOSPHOLIPASE C; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 1842406597     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970611)71:6<1049::AID-IJC22>3.0.CO;2-7     Document Type: Article

References (30)

1. BJØRGE, L.,. HAKULINEN, J., WAHLSTRÖM, T., MATRE, R. and MERI, S., Complement regulatory proteins in ovarian malignancies. Int. J. Cancer 70, 14-25 (1997).
2. DAHIYA, R., BOYLE, B., GODBKRG, B.C., YOON, W.H., KONETY, B., CHEN, K., YEN, T.S., BLUMENFELD, W. and NARAYAN, P., Metastasis-associated alterations in phospholipids and fatty acids of human prostatic adenocarcinoma cell lines. Biochem. Biol., 70, 548-554 (1992).
3. DAVIES, A. and LACHMANN, P.J., Membrane defense against complement lysis: the structure and biological properties of CD59. Immunol. Res., 12, 258-275 (1993).
4. DECKERT, M., TICCHIONI, M. and BERNARD, M., Endocytosis of GPIanchored proteins in human lymphocytes: role of glycolipid-based domains, act in cytoskeleton, and protein kinases. J. Cell Biol., 133, 791-799 (1996).
5. GLEASON, D.F., MELLINGER, G.T. and THE VETERANS ADMINISTRATION COOPERATIVE UROLOGICAL RESEARCH GROUP, Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol., 111, 58-64 (1974).
6. GORTER, A., BLOK, V.T., HAASNOOT, W.H., ENSINK, N.G., DAHA, M.R. and FLEUREN, G.J., Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis. Lab. Invest., 74, 1039-1049 (1996).
7. GUIDI, L., BARONI, R., BARTOLONI, C., PELLEGRINO, M., TRICERRI, A., MARCIANO, M., BARONE, C. und GAMBASSI, G., Immune complexes in solid tumours precipitable by 3.5% polyethylene glycol: analysis of some nonspecific components. Diag, clin. Immunol. 5, 284-288 (1988).
8. HAKULINEN, J. and MERI, S., Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells. Lab. Invest., 71, 820-827 (1994).
9. HAYWARD, S.W., DAHIYA, R., CUNHA, G.R., BARTEK, J., DESHPANDE, N, and NARAYAN, P., Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell. Dev. Biol., 31A, 14-24 (1995).
10. HODGE, J.W., SCHLOM, J., DONOHUE, S.J., TOMASZEWSKI, J.E., WHEELER, C.W., LEVINE, B.S., GRITZ, L., PANICALI, D. and KANTOR, J.A., A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int. J. Cancer, 63, 231-237 (1995).
11. HOROSZEWICZ, J.S., LEONG, S.S., KAWINSKI, E., KARR, J.P., ROSENTHAL, H., CHU, T.M., MIRAND, E.A. and MURPHY, G.P., LNCaP model of human prostatic carcinoma. Cancer Res., 43, 1809-18 (1983).
12. JOKIRANTA, T.S. and MERI, S., Biotinylation of monoclonal antibodies prevents their ability to activate the classical pathway of complement. J. Immunol. 151, 2124-2131 (1993).
13. KAIGHN, M.E., NARAYAN, K.S., OHNUKI, Y., LECHNER, J.F. and JONES, L.W., Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol., 17, 16-23 (1979).
14. MÄENPÄÄ, A., JUNNIKKALA, S., HAKULINEN, J., TlMONEN, T. and MERI, S., Expression of complement membrane regulators membrane cofactor protein (CD46). decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Amer. J. Pathol., 148, 1139-1152 (1996).
15. MERI, S., Protectin (CD59): complement lysis inhibitor and prototype domain in a new protein superfamily. Immunologist, 2, 149-155 (1994).
16. MERI, S., LEHTO, T., SUTTON, C.W., TYYNELÄ. J. and BAUMANN, M., Structural composition and functional characterization of soluble CD59: heterogeneity of the oligosaccharide and glycophosphoinositol (GPL)anchor revealed by laser-desorption mass spectrometric analysis. Biochem. y., 316, 923-935 (1996).
17. MERI, S., MATTILA, P. and RENKONEN, R., Regulation of CD59 expression on the human endothelial cell line EA.hy 926. Europ. J. Imnnmol., 23, 2511-2516 (1993).
18. MERI, S., MORGAN, B.P., DAVIES, A., DANIELS, R.H., OLAVESEN, M.G., WALDMANN, H. and LACHMANN, P.J., Human protectin (CD59). an 18.000 20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology. 71, 1-9 (1990).
19. MERI, S., WALDMANN, H. and LACHMANN, P.J., Distribution of protectin (CD59). a complement membrane attack inhibitor, in normal human tissues. Lab. Invest., 65, 532-537 (1991).
20. MORGAN, B.P., Effects of the membrane attack complex of complement on nucleated cells. Our. Topics Microbiol. Immunol., 178, 115-140 (1992).
21. MORGAN, B.P. and MERI, S., Membrane proteins that protect against complement lysis. Springer Semin. Immunopathol., 15, 369-96 (1994).
22. NARAYAN, P. and DAHIYA, R., Establishment and characterization of a human primary prostatic adenocarcinoma cell line (ND-1). J. Urol., 148, 1600-1604 (1992).
23. NICULESCU, F., Rus, H.G., RETEGAN, M. and VLAICU, R., Persistent complement activation on tumor cells in breast cancer. Amer. J. Pathol., 140, 1039-1043 (1992).
24. PANGBURN, M.K., Activation of complement via the alternative pathway. Fed. Proc., 42, 139-143 (1983).
25. REITER, Y., CIOBOTARIU, A. and FISHELSON, Z., Sublytic complement attack protects tumor cells from lytic doses of antibody and complement. Europ. J. Immunol., 22, 1207-1213 (1992).
26. ROONEY, I.A., ATKINSON, J.P., KRUL, E.S., SCHONFELD, G., POLAKOSKI, K., SAFFITZ, J.E. and MORGAN, B.P., Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organdies (prostasomes). binds cell membranes, and inhibits complement-mediated lysis. J. exp. Med., 177, 1409-1420 (1993).
27. SIMPSON, K.L. and HOLMES, C.H., Differential expression of complement regulatory proteins decay-accelerating factor (CD55). membrane cofactor protein (CD46) and CD59 during human spermatogenesis. Immunology. 81, 452-461 (1994).
28. STONE, K.R., MICKEY, D.D., WUNDERLI, H., MICKEY, G.H. and PAULSON, D.F., Isolation of a human prostalic carcinoma cell line (DU-145). Int. J. Cancer, 21, 274-281 (1978).
29. VOGEL, C.-W., Complement, a biologic effector mechanism for tumor cell killing. Immunol. Allergy Clin. North Anwr., 11, 277-299 (1991).
30. YAMAKAWA, M., YAMADA, K., TSUGE, T., OHRUI, H., OGATA, T., DOBASHI, M. and IMAI, Y., Protection of thyroid cancer cells by complementregulatory factors. Cancer, 73, 2808-2817 (1994).